This is the authors' abstract. We don't add key points for this paper.
The metabolic process of chiral drugs plays a significant role in clinics and in research on drugs.Here, we experimentally demonstrate by all-optical means that the chiral molecules can be quickly discriminated and monitored with the ultrahighorder modes excited in a metal cladding optofluidic chip, achieving over 5 times sensitivity with a low-dosage sample.We show that the varying concentration of the chiral drugs can be monitored both in cell and animal experiments, presenting a significant difference between chiral enantiomers at the optimal function time and the effect of the reaction.To our knowledge, this approach provides a new way to achieve important chiral discrimination for the pharmacokinetics and the pharmacodynamics and may present opportunities in indicating the health status of humans.
No takes yet. Share an insight, caveat, or question.
Wei et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: